CMPS Stock Analysis: Compass Pathways | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.717m USD | 12M Return: 266.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 45.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
COMPASS Pathways plc (NASDAQ: CMPS) is a UK-headquartered biotechnology company developing psychedelic-based therapies for mental health conditions. Its lead investigational product, COMP360, is a synthetic psilocybin formulation currently in Phase III clinical trials for treatment-resistant depression (TRD), and in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. The company operates in both the United Kingdom and the United States, and went public on NASDAQ in September 2020 at a small-cap valuation.
The company was originally incorporated as COMPASS Rx Limited and rebranded to COMPASS Pathways plc in August 2020. Psilocybin is a naturally occurring psychoactive compound that is being investigated by a small group of clinical-stage biotech firms as a potential treatment for psychiatric disorders where existing therapies have shown limited effectiveness, representing an emerging frontier within the broader mental health therapeutics market.
- Phase III COMP360 psilocybin data readout in treatment-resistant depression approaches
- FDA breakthrough therapy designation shapes accelerated regulatory pathway
- Cash burn widens as operating losses outpace no product revenue
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA 15.13 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -159.5m > Net Income -178.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.6m) vs 12m ago 4.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -36.47 > 6 (EBIT TTM -176.8m / Interest Expense TTM 4.85m) |
| A: 0.67 (Total Current Assets 510.9m - Total Current Liabilities 153.8m) / Total Assets 531.7m |
| B: -1.38 (Retained Earnings -731.4m / Total Assets 531.7m) |
| C: -0.42 (EBIT TTM -176.8m / Avg Total Assets 425.4m) |
| D: 1.59 (Book Value of Equity 326.7m / Total Liabilities 205.1m) |
| Altman-Z'' = -1.20 = CCC |
As of July 12, 2026, the stock is trading at USD 13.64 with a total of 4,181,669 shares traded. Over the past week, the price has changed by +0.15%, over one month by +23.66%, over three months by +146.65% and over the past year by +266.67%.
Current recommended Stop Loss: 12.40 (which is 9.1% or 1.2 ATR below the current price).
Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.3 | 63.7% |
P/B = 5.6303
Revenue TTM = 0.0 USD
EBIT TTM = -176.8m USD
EBITDA TTM = -176.6m USD
Long Term Debt = 50.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.05m USD (from shortTermDebt, last quarter)
Debt = 55.4m USD (corrected: LT Debt 50.5m + ST Debt 2.05m) + Leases 2.83m
Net Debt = -410.6m USD (calculated: Debt 55.4m - CCE 466.0m)
Enterprise Value = 1.31b USD (1.72b + Debt 55.4m - CCE 466.0m)
Interest Coverage Ratio = -36.47 (Ebit TTM -176.8m / Interest Expense TTM 4.85m)
EV/FCF = -8.19x (Enterprise Value 1.31b / FCF TTM -159.5m)
FCF Yield = -12.21% (FCF TTM -159.5m / Enterprise Value 1.31b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 217k) / Revenue TTM)
Tobins Q-Ratio = 2.46 (Enterprise Value 1.31b / Total Assets 531.7m)
Interest Expense / Debt = 8.76% (Interest Expense 4.85m / Debt 55.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -139.7m (EBIT -176.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.32 (Total Current Assets 510.9m / Total Current Liabilities 153.8m)
Debt / Equity = 0.17 (Debt 55.4m / totalStockholderEquity, last quarter 326.7m)
Debt / EBITDA = 2.33 (negative EBITDA) (Net Debt -410.6m / EBITDA -176.6m)
Debt / FCF = 2.57 (negative FCF - burning cash) (Net Debt -410.6m / FCF TTM -159.5m)
Total Stockholder Equity = 118.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.03% (Net Income -178.8m / Total Assets 531.7m)
RoE = -150.9% (Net Income TTM -178.8m / Total Stockholder Equity 118.5m)
RoCE = -104.7% (out of range, set to none) (EBIT -176.8m / Capital Employed (Equity 118.5m + L.T.Debt 50.5m))
RoIC = -36.76% (negative operating profit) (NOPAT -139.7m / Invested Capital 380.0m)
WACC = 12.09% (E(1.72b)/V(1.77b) * Re(12.26%) + D(55.4m)/V(1.77b) * Rd(8.76%) * (1-Tc(0.21)))
Discount Rate = 12.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 20.14%
[DCF] Fair Price = unknown (Cash Flow -159.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.31 | Chg30d=+2.63% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.31 | Chg30d=+9.19% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.99 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+43.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.06 | Chg30d=+11.57% | Revisions=+25% | GrowthEPS=-6.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=1, down=1)